Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Titel:
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Auteur:
Francini, Edoardo Yip, Steven Ahmed, Shubidito Li, Haocheng Ardolino, Luke Evan, Carolyn P. Kaymakcalan, Marina Shaw, Grace K. Kantoff, Philip W. Taplin, Mary-Ellen Alimohamed, Nimira S. Joshua, Anthony M. Heng, Daniel Y.C. Sweeney, Christopher J.